Mesa Laboratories has entered into a definitive agreement to acquire Agena Bioscience for a cash purchase price of $300 million.
The transaction is expected to be completed in Mesa’s third fiscal quarter ending December 31, 2021.
Agena, based in San Diego, CA, develops high-throughput genetic analysis solutions for clinical labs. The company’s MassArray system integrates mass spectroscopy and multiplex PCR. Peter Dansky, Chief Executive Officer of Agena, will join Mesa to lead the new Clinical Genomics Division.
Mesa develops quality control solutions for the pharmaceutical, healthcare, and medical device industries.
